M. Shawi

1.4k citations

85 papers · 982 indexed · h-index 19

Co-authors: Chantal Autexier Alexa P. Kollmeier Soumya D. Chakravarty Philip J. Mease Xie L. Xu Shihong Sheng Iain B. McInnes Chetan S. Karyekar
Topics: Psoriasis: Treatment and Pathogenesis (55 papers)Spondyloarthritis Studies and Treatments (51 papers)Rheumatoid Arthritis Research and Therapies (37 papers)
Cited by: Rheumatology Hematology Immunology
Journals: PLoS ONE The Journal of Infectious Diseases International Journal of Cancer
Partner nations: United States Canada United Kingdom

In The Last Decade

M. Shawi

77 papers receiving 972 citations

Peers

Countries citing papers authored by M. Shawi

Since Specialization

Citations

This map shows the geographic impact of M. Shawi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Shawi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Shawi more than expected).

Fields of papers citing papers by M. Shawi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Shawi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Shawi. The network helps show where M. Shawi may publish in the future.

Co-authorship network of co-authors of M. Shawi

This figure shows the co-authorship network connecting the top 25 collaborators of M. Shawi. A scholar is included among the top collaborators of M. Shawi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Shawi. M. Shawi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis 2024 ·Clinical Rheumatology ·Proton Rahman,Iain B. McInnes,Atul Deodhar,Georg Schett,Phillip J. Mease,M. Shawi,J. Daniel,Jonathan Sherlock,Alexa P. Kollmeier,Xie L. Xu,Shihong Sheng,Christopher T. Ritchlin,Dennis McGonagle	0
2	Early Improvements with Guselkumab Associate with Sustained Control of Psoriatic Arthritis: Post hoc Analyses of Two Phase 3 Trials 2024 ·Rheumatology and Therapy ·Jeffrey R. Curtis,Atul Deodhar,Enrique R. Soriano,Emmanouil Rampakakis,M. Shawi,Natalie J. Shiff,Cheng‐Long Han,William Tillett,(unknown)	2
3	Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis 2024 ·Arthritis & Rheumatology ·Stefan Siebert,Laura C. Coates,Georg Schett,S. P. Raychaudhuri,(unknown),Sheng Gao,Loqmane Seridi,Soumya D. Chakravarty,M. Shawi,F. Lavie,(unknown),(unknown),Alexa P. Kollmeier,Xie L. Xu,Proton Rahman,Philip J. Mease,Atul Deodhar	4
4	Persistent Patient‐Level Effect of Guselkumab at Consecutive 8‐Week Dosing Visits and Over Time in Patients With Active Psoriatic Arthritis: Post Hoc Analysis of a 2‐Year, Phase 3, Randomized, Controlled Study 2024 ·ACR Open Rheumatology ·Philip J. Mease,Xenofon Baraliakos,Vinod Chandran,Enrique R. Soriano,Peter Nash,Atul Deodhar,Emmanouil Rampakakis,Natalie J. Shiff,Soumya D. Chakravarty,M. Shawi,Joseph F. Merola,Iain B. McInnes	2
5	Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study 2024 ·Clinical Rheumatology ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,Soumya D. Chakravarty,Emmanouil Rampakakis,M. Shawi,Elena Schiopu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	1
6	AB1088 EARLY CLINICAL IMPROVEMENT AS PREDICTOR OF LONG-TERM HEALTH-RELATED QUALITY OF LIFE IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS THROUGH 2 YEARS OF A PHASE-3 STUDY 2023 ·Annals of the Rheumatic Diseases ·(unknown),Enrique R. Soriano,Lai‐Shan Tam,Natalie J. Shiff,M. Shawi,(unknown),John J. Curtis	1
7	AB1104 STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY 2023 ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,(unknown),(unknown),M. Shawi,Elena Schiopu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	2
8	POS1522 CHANGES IN SERUM CYTOKINES BY WEEK 24 CORRELATE WITH LONG-TERM EFFICACY OF GUSELKUMAB THROUGH 2-YEARS IN BIO-NAÏVE ADULTS WITH PSA 2023 ·Annals of the Rheumatic Diseases ·Stefan Siebert,Georg Schett,S. P. Raychaudhuri,Mónica Gumá,(unknown),Sheng Gao,(unknown),M. Shawi,Proton Rahman	1
9	POS0227 SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS 2023 ·Annals of the Rheumatic Diseases ·Signe Holm Nielsen,Anne‐Christine Bay‐Jensen,Peder Frederiksen,M.A. Karsdal,M. Shawi,(unknown),Alexa P. Kollmeier,(unknown),Sheng Gao	0
10	POS1535 EARLY IMPROVEMENT IN 3VAS/4VAS PREDICTS REDUCED RATES OF RADIOGRAPHIC CHANGE IN BIO-NAIVE ACTIVE PSORIATIC ARTHRITIS PATIENTS RECEIVING GUSELKUMAB TREATMENT 2023 ·Annals of the Rheumatic Diseases ·William Tillett,Laura C. Coates,Marijn Vis,Enrique R. Soriano,Joseph F. Merola,M Zimmermann,M. Shawi,(unknown),Peter Nash,Philip Helliwell	2
11	Guselkumab, a Selective Interleukin‐23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies 2023 ·ACR Open Rheumatology ·Dennis McGonagle,Iain B. McInnes,Atul Deodhar,Georg Schett,M. Shawi,Soumya D. Chakravarty,Alexa P. Kollmeier,Xie L. Xu,Shihong Sheng,Stephen Xu,Christopher T. Ritchlin,Proton Rahman,Phillip J. Mease	4
12	Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis 2023 ·Drug Safety ·Bruce Strober,Laura C. Coates,Mark Lebwohl,Atul Deodhar,(unknown),(unknown),Alexa P. Kollmeier,Megan Miller,Yanli Wang,Shu Li,Soumya D. Chakravarty,Daphne Chan,M. Shawi,Ya‐Wen Yang,(unknown),Proton Rahman	31
13	Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes 2023 ·BMJ Open ·Peter Nash,Jan Dutz,(unknown),Barkha P. Patel,(unknown),M. Shawi,(unknown),James Cheng‐Chung Wei	4
14	Efficacy of Guselkumab on Axial-Related Symptoms Through up to 2 Years in Adults with Active Psoriatic Arthritis in the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Study 2023 ·Rheumatology and Therapy ·Philip J. Mease,Dafna D. Gladman,Denis Poddubnyy,Soumya D. Chakravarty,M. Shawi,Alexa P. Kollmeier,Xie L. Xu,Stephen Xu,Atul Deodhar,Xenofon Baraliakos	11
15	Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies 2022 ·RMD Open ·Christopher T. Ritchlin,Philip J. Mease,Wolf‐Henning Boehncke,John Tesser,Elena Schiopu,Soumya D. Chakravarty,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,(unknown),Shihong Sheng,Yanli Wang,Stephen Xu,Joseph F. Merola,Iain B. McInnes,Atul Deodhar	18
16	Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis 2022 ·Lara D. Veeken ·Laura C. Coates,Christopher T. Ritchlin,Laure Gossec,Philip Helliwell,Proton Rahman,Alexa P. Kollmeier,Xie L. Xu,M. Shawi,Chetan S. Karyekar,(unknown),W. Noël,Shihong Sheng,Yanli Wang,Stephen Xu,Philip J. Mease	11
17	AB0892 Targeted Safety Analyses of Guselkumab: Long-Term Results from Randomized Clinical Trials in Patients with Active Psoriatic Arthritis and Moderate to Severe Psoriasis 2022 ·Annals of the Rheumatic Diseases ·Philip J. Mease,(unknown),(unknown),(unknown),M. Shawi,Ya‐Wen Yang,Megan Miller,Alexa P. Kollmeier,X. L. Xu,Jingxue Yu,(unknown),(unknown),(unknown),Iain B. McInnes	1
18	POS1070 BASELINE DETERMINANTS OF PAIN RESPONSE IN PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB 2022 ·Annals of the Rheumatic Diseases ·Peter Nash,Christopher T. Ritchlin,Proton Rahman,M. Shawi,(unknown),(unknown),Alexa P. Kollmeier,X. L. Xu,(unknown),(unknown),Saakshi Khattri,Enrique R. Soriano,D. Mcgonagle	1
19	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis 2021 ·Arthritis & Rheumatology ·Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,(unknown),Shihong Sheng,M. Shawi,Soumya D. Chakravarty,Désirée van der Heijde,Philip J. Mease	66
20	Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry 2014 ·Arthritis Care & Research ·Carter Thorne,W. Bensen,D. Choquette,(unknown),Majed Khraishi,Christopher J. Atkins,(unknown),A.J. Lehman,M. Shawi,Hayssam Khalil,F. Nantel,Emmanouil Rampakakis,John S. Sampalis,(unknown)	23

About M. Shawi

M. Shawi is a scholar working on Rheumatology, Immunology and Hematology, having authored 85 papers that have together received 982 indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (55 papers), Spondyloarthritis Studies and Treatments (51 papers) and Rheumatoid Arthritis Research and Therapies (37 papers). The work is most often cited by research in Rheumatology (515 citations), Hematology (311 citations) and Immunology (543 citations). M. Shawi has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Chantal Autexier, Alexa P. Kollmeier, Soumya D. Chakravarty, Philip J. Mease, Xie L. Xu, Shihong Sheng, Iain B. McInnes, Chetan S. Karyekar, Elizabeth C. Hsia and Proton Rahman. Their work appears in journals such as PLoS ONE, The Journal of Infectious Diseases and International Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact